Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
3-6-2020

Inhibition of radiographic progression across levels of composite
index-defined disease activity in patients with active psoriatic
arthritis treated with intravenous golimumab: results from a
phase-3, double-blind, placebo-controlled trial.
Philip Mease
Seattle Rheumatology Associates, Swedish Medical Center/Providence St. Joseph Health

M Elaine Husni
Shelly Kafka
Soumya D Chakravarty
Diane D Harrison

See next page for additional authors
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Rheumatology Commons

Recommended Citation
Mease, Philip; Husni, M Elaine; Kafka, Shelly; Chakravarty, Soumya D; Harrison, Diane D; Lo, Kim Hung; Xu,
Stephen; Hsia, Elizabeth C; and Kavanaugh, Arthur, "Inhibition of radiographic progression across levels of
composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous
golimumab: results from a phase-3, double-blind, placebo-controlled trial." (2020). Articles, Abstracts, and
Reports. 2900.
https://digitalcommons.psjhealth.org/publications/2900

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St.
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.

Authors
Philip Mease, M Elaine Husni, Shelly Kafka, Soumya D Chakravarty, Diane D Harrison, Kim Hung Lo,
Stephen Xu, Elizabeth C Hsia, and Arthur Kavanaugh

This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/2900

Mease et al. Arthritis Research & Therapy
https://doi.org/10.1186/s13075-020-2126-1

(2020) 22:43

RESEARCH ARTICLE

Open Access

Inhibition of radiographic progression
across levels of composite index-defined
disease activity in patients with active
psoriatic arthritis treated with intravenous
golimumab: results from a phase-3, doubleblind, placebo-controlled trial
Philip Mease1* , M. Elaine Husni2, Shelly Kafka3, Soumya D. Chakravarty3,4, Diane D. Harrison5, Kim Hung Lo5,
Stephen Xu5, Elizabeth C. Hsia5,6 and Arthur Kavanaugh7

Abstract
Background: In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly
inhibited radiographic progression. In post hoc analyses, we evaluated changes in total PsA-modified Sharp/van der
Heijde scores (SHS) across levels of composite index-defined disease activity following treatment.
Methods: In this phase-3, double-blind, placebo-controlled trial, 480 bio-naïve patients with active PsA randomly
received intravenous golimumab 2 mg/kg (N = 241; week 0, week 4, every 8 weeks [q8w]) or placebo (N = 239;
week 0, week 4, week 12, week 20) followed by golimumab (week 24, week 28, q8w) through week 52. Week 24
and week 52 SHS changes in patient subgroups, defined by levels of disease activity as assessed by several
composite measures (minimal disease activity [MDA], very low disease activity [VLDA], Psoriatic ArthritiS Disease
Activity Score [PASDAS], Disease Activity in Psoriatic Arthritis [DAPsA], Clinical Disease Activity Index [CDAI]), were
evaluated post hoc in 474 patients with evaluable radiographic data. Partially (last-observation-carried-forward
methodology) and completely (nonresponder methodology) missing data were imputed.
Results: Across indices, golimumab-treated patients demonstrated less radiographic progression than placebotreated patients, regardless of disease activity state achieved via golimumab, from week 0 to 24 (e.g., mean changes
in PsA-modified SHS were − 0.83 vs. 0.91, respectively, in patients achieving MDA and − 0.05 vs. 1.49, respectively, in
those not achieving MDA). Treatment differences observed at week 24 persisted through week 52, despite placeborandomized patients crossing over to golimumab at week 24 (e.g., mean changes in PsA-modified SHS from week 0
to 52 for golimumab- vs. placebo→golimumab-treated patients achieving MDA were − 1.16 vs. 1.19, respectively)
and regardless of whether low disease activity was achieved (0.03 vs. 1.50, respectively, in those not achieving
MDA). Consistent patterns were observed for disease activity assessed using VLDA, PASDAS, DAPsA, and CDAI
composite endpoints.
(Continued on next page)
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Conclusions: The extent of structural damage inhibition afforded by up to 1 year of intravenous golimumab
treatment paralleled levels of PsA activity, with greater progression of structural damage observed in patients with
sustained higher disease activity. Among patients not achieving low levels of disease activity across several
composite indices, golimumab-randomized patients appeared to exhibit far less progression of structural damage
than placebo-randomized PsA patients, illustrating a potential disconnect between responses, wherein golimumab
can inhibit structural damage independent of clinical effect.
Trial registration: ClinicalTrials.gov. NCT02181673. Registered 04 July 2014.
Keywords: Psoriatic arthritis, Intravenous golimumab, Anti-TNF therapy, Biologic therapy, Radiographic progression,
Composite indices

Introduction
Psoriatic arthritis (PsA) is an immune-mediated inflammatory disorder characterized by a wide array of clinical
manifestations, including axial and peripheral arthritis,
psoriatic lesions, nail disease, enthesitis, dactylitis, impairment of physical function, and lower levels of reported health-related quality of life (HRQoL). The
burden of PsA to the individual can be severe, with some
patients developing destructive arthritis leading to bony
erosion and loss of joint architecture. In an early PsA cohort, after 1–5 years, 47% of patients had ≥ 1 erosion,
despite conventional treatment [1]. Bone erosions in patients with PsA, which appear to differ from those observed in rheumatoid arthritis (RA), can be quite
extensive and contribute to significant joint deformity
and disability [2].
Given that PsA manifestations may vary over time
within individuals, and respond differently to therapy
[3], and patients expect biologic agents to effectively
treat all aspects of disease, physicians need to assess disease activity and patient overall response to include all
aspects. Specifically, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and
Outcome Measures in Rheumatology (OMERACT) have
concluded that remission of both disease- and patientspecific symptoms should be the ideal target, with low
or very low disease activity being reasonable alternatives
under certain circumstances [4, 5].
Composite scores, which combine different assessments
into a single index, offer an efficient method for assessing
disease activity in a disorder with heterogeneous manifestations such as PsA. The recently published American
College of Rheumatology-National Psoriasis Foundation
treatment recommendations for PsA highlight the difficulties in assessing efficacy in PsA with a single algorithm,
owing not only to the high degree of heterogeneity in the
presentation and course of PsA, but also to involvement
of multiple domains in a single patient [3]. Not surprisingly, the GRAPPA-OMERACT group has not yet reached
consensus on the use of a specific index, as existing indices have both advantages and disadvantages and require

further validation [5]. Consensus was obtained, however,
on the concept that composite indices should include
musculoskeletal disease/peripheral arthritis, skin disease,
and disease impact/HRQoL [5].
Golimumab (Janssen Biotech Inc., Horsham, PA, USA)
is a fully human anti-tumor necrosis factor alpha (TNFα)
monoclonal antibody shown to be effective in patients
with RA, ankylosing spondylitis, and PsA [6]. Specific to
PsA, sustained clinical efficacy and inhibition of structural
damage was observed in patients with moderate-to-severe
PsA in both the GO-REVEAL trial of subcutaneous (SC)
golimumab [7, 8] and the GO-VIBRANT trial of intravenous (IV) golimumab [9, 10]. Given the importance of further evaluating the utility of composite indices to assess
diverse manifestations in patients with PsA, we conducted
post hoc analyses of data from GO-VIBRANT to assess
changes in radiographic progression at 6 months and 1
year in patients with varying levels of composite indexdefined disease activity following treatment during both
the controlled and uncontrolled study periods.

Methods
Patients and study design

Details of the GO-VIBRANT study design and participant eligibility criteria have been reported [9, 10]. Briefly,
eligible patients were bio-naïve, had PsA based on the
ClASsification of Psoriatic ARthritis (CASPAR) criteria
[11] for ≥ 6 months, and demonstrated active disease
(swollen joint count [SJC] ≥ 5 and tender joint count
[TJC] ≥ 5 at screening and baseline and screening Creactive protein [CRP] ≥ 0.6 mg/dL), despite therapy with
disease-modifying antirheumatic drugs (≥ 3 months)
and/or nonsteroidal anti-inflammatory drugs (≥ 4 weeks)
or an intolerance to these therapies. Participants also
had active or a documented history of plaque psoriasis.
Enrolled patients were randomly assigned (1:1) to receive IV infusions of golimumab 2 mg/kg at weeks 0, 4,
and every 8 weeks (q8w) thereafter or placebo at weeks
0, 4, 12, and 20. Stable doses of methotrexate (MTX;
≤ 25 mg/week) were permitted for patients receiving this
treatment for ≥ 3 months prior to study start, and stable
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doses of nonsteroidal anti-inflammatory drugs and lowdose oral corticosteroids were permitted for patients receiving them for ≥ 2 weeks. Patients with < 5% improvement in SJC and TJC at week 16 could enter early
escape, wherein specific changes in concomitant medications were permitted. At week 24, all patients in the placebo group crossed over to receive golimumab 2 mg/kg
at week 24, week 28, and q8w thereafter. The final study
agent infusion was at week 52.

Clinical assessments and composite endpoints

The primary outcome measure was the American College of Rheumatology 20% improvement (ACR20) response criteria [12]. An independent joint assessor
determined the TJC (N = 68) and SJC (N = 66). Patients
assessed pain using a visual analog scale (VAS; 0–10 cm
or 0–100 mm), and both patients and physicians
assessed global disease activity with a VAS. Patients
assessed physical function using the Health Assessment
Questionnaire-Disability Index (HAQ-DI; score range,
0–3) [13]. Serum CRP concentrations were also determined (upper limit of normal, 0.287 mg/dL).
The independent joint assessor evaluated the presence
(1) or absence (0) of enthesitis in each lateral elbow epicondyle, medial femoral condyle, and Achilles tendon insertion point using the PsA-specific Leeds Enthesitis
Index (LEI; score range, 0–6) [14]. In each of 20 digits,
the independent joint assessor assessed dactylitis as absent (0), mild (1), moderate (2), or severe (3), with a total
score range of 0–60 [15, 16]. Among patients with ≥ 3%
body surface area (BSA) involvement at baseline, psoriasis was assessed using the Psoriasis Area and Severity
Index (PASI) [17].
Several composite measures of disease activity were
employed in our analyses. Patients meeting five or more
of the following seven criteria were determined to have
minimal disease activity (MDA): TJC ≤ 1, SJC ≤ 1, PASI
≤ 1 among patients with BSA ≥ 3%, patient pain VAS
≤ 15 mm, patient global VAS ≤ 20 mm, HAQ-DI ≤ 0.5, and
LEI ≤ 1. Patients meeting all seven criteria were deemed to
have achieved very low disease activity (VLDA; evaluated
post hoc) [18, 19]. Additional composite measures,
determined post hoc employing component data available from preplanned study assessments, included the
Psoriatic ArthritiS Disease Activity Score (PASDAS),
the Disease Activity in Psoriatic Arthritis (DAPsA)
score, and the Clinical Disease Activity Index (CDAI).
The PASDAS [20, 21] was calculated using patient global disease activity VAS (arthritis and psoriasis), physician global disease activity VAS, 68-joint TJC, 66-joint
SJC, CRP, enthesitis (LEI), dactylitis (scores of 0–3
recoded to 0–1, where any score > 0 equaled 1; range,
0–20) [22], and the physical component summary score
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of the 36-item Short Form Health Survey [23]. Disease
activity cutoffs were remission (≤ 1.9), low (> 1.9–< 3.2),
moderate (≥ 3.2–< 5.4), and high (≥ 5.4) [24]. The
DAPsA score was calculated as the sum of the 68-joint
TJC, 66-joint SJC, CRP, patient pain VAS, and patient
global disease activity VAS [21]. The disease activity
cutoffs were remission (≤ 4), low (> 4–≤ 14), moderate
(> 14–≤ 28), and high (> 28) [25]. The CDAI (range, 0–
76), a composite index validated to assess disease activity in RA patients and also employed in clinical practice
to assess PsA disease activity, was calculated as the sum
of the 28-joint TJC, 28-joint SJC, patient global disease
activity VAS, and physician global disease activity VAS.
The disease activity cutoffs were remission (≤ 2.8), low
(> 2.8–≤ 10), moderate (> 10–≤ 22), and high (> 22) [26].
Note that MDA was the only one of these composite
endpoints prespecified in the overarching clinical trial.

Radiographic assessments

Radiographs of the hands (posteroanterior) and feet (anteroposterior) obtained at weeks 0, 24, and 52 (or at the
time of early discontinuation) were centrally read by two
independent and blinded readers [27] and scored using
the total Sharp/van der Heijde score (SHS) with modifications for patients with PsA, i.e., inclusion of distal interphalangeal joints in the hands, as well as pencil-in-cup
and gross osteolysis deformities [28, 29]. The total PsAmodified SHS (range, 0–528) sums the erosion (0–320)
and joint space narrowing (JSN; 0–208) scores for 40 hand
and 12 foot joints. Severity of JSN is scored as 0 (no JSN),
1 (asymmetrical or < 25% JSN), 2 (25 to < 50% JSN), 3
(50–99% JSN or subluxation), or 4 (absence of a joint
space, presumptive evidence of ankylosis, or complete luxation) [29]. Higher SHSs and more positive change scores
indicate more existing radiographic damage and more
radiographic progression, respectively.

Data analysis

In this post hoc analysis, we assessed changes in the
total PsA-modified SHS from week 0 to week 24 and
from week 0 to week 52 according to disease activity
state achieved at week 24 and week 52, respectively, as
assessed by the MDA, VLDA, PASDAS, DAPsA, and
CDAI composite indices. Partially missing (last-observation-carried-forward methodology) and completely missing (nonresponder methodology) clinical efficacy data
were imputed. Linear extrapolation was employed to impute missing SHS data. At week 24, treatment group
comparisons within disease activity state subgroups
employed analysis of variance on the van der Waerdennormal scores with no adjustment for multiplicity of
testing. Thus, reported p values are descriptive in nature.
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Results
Patient disposition and baseline characteristics

Patient disposition through week 24 [9] and week 52
[10] of GO-VIBRANT has been reported. Briefly, data
were collected from September 2014 to March 2017 at
90 sites in 11 European and North American countries.
In total, 480 patients contributed data to the efficacy
analyses, including 239 in the placebo group and 241 in
the golimumab group. Of these, 474 patients contributed
data to structural damage analyses, including 237 in each
of the placebo and golimumab groups [27]. Demographic and disease characteristics were generally wellbalanced between the treatment groups, including

baseline radiographic findings and disease activity. Approximately one half of patients had dactylitis, two thirds
had enthesitis, and more than 80% had ≥ 3% BSA psoriasis skin involvement at baseline. Use of MTX (mean
dose, 15 mg/week) and oral corticosteroids (mean dose,
7.5 mg/day) was reported by 70% and 28% of patients,
respectively, at baseline (Table 1).
PsA-modified SHS through week 24 and week 52

Individual reader assessments of the change from baseline in the total PsA-modified SHS were generally consistent with each other. The intra-class correlation
coefficients for baseline and week 52 scores were 0.84

Table 1 Baseline patient and disease characteristics
IV placebo

IV golimumab, 2 mg/kg

All patients

Number of patients

239

241

480

Age (years), mean (SD)

46.7 (12.5)

45.7 (11.3)

46.2 (11.9)

Male, n (%)

121 (50.6)

128 (53.1)

249 (51.9)

White, n (%)

237 (99.2)

241 (100)

478 (99.6)

Body mass index (kg/m2), mean (SD)

28.9 (6.2)

28.9 (6.4)

28.9 (6.3)

Duration of PsA (years), mean (SD)

5.3 (5.9)

6.2 (6.0)

5.8 (6.0)

Swollen joint count (0–66), mean (SD)

14.1 (8.2)

14.0 (8.4)

14.0 (8.3)

Tender joint count (0–68), mean (SD)

26.1 (14.4)

25.1 (13.8)

25.6 (14.1)

Patient pain VAS (0–10), mean (SD)

6.4 (2.1)

6.3 (2.1)

6.3 (2.1)

Patient global disease activity VAS (0–10), mean (SD)

6.3 (2.1)

6.5 (1.9)

6.4 (2.0)

Physician global disease activity VAS (0–10), mean (SD)

6.4 (1.6)

6.2 (1.7)

6.3 (1.6)

≥ 3% BSA psoriasis skin involvement, n (%)

198 (82.8)

196 (81.3)

394 (82.1)

1

PASI score (0–72), mean (SD)

8.9 (9.0)

11.0 (9.9)

9.9 (9.5)

PASDAS, mean (SD)2

6.7 (1.1)

6.7 (1.1)

6.7 (1.1)

DAPsA, mean (SD)3

72.8 (32.1)

71.8 (34.0)

72.3 (33.0)

CDAI score (0–76), mean (SD)2

34.4 (13.1)

33.3 (12.5)

33.8 (12.8)

HAQ-DI (0–3), mean (SD

1.3 (0.6)

1.3 (0.6)

1.3 (0.6)

C-reactive protein (mg/dL), mean (SD)

2.0 (2.1)

1.9 (2.5)

2.0 (2.3)

Patients with dactylitis, n (%)
Dactylitis score (1–60)4, mean (SD)
Patients with enthesitis, n (%)
Leeds Enthesitis Index score (1–6)4, mean (SD)
Total PsA-modified SHS (0–528), mean (SD)

124 (51.9)

134 (55.6)

258 (53.8)

9.9 (10.1)

9.3 (9.4)

9.6 (9.7)

181 (75.7)

185 (76.8)

366 (76.3)

3.2 (1.6)

3.0 (1.6)

3.1 (1.6)

34.5 (53.5)

35.5 (55.2)

35.0 (54.3)

173 (72.4)

163 (67.6)

336 (70.0)

14.9 (4.8)

14.8 (4.7)

14.8 (4.7)

67 (28.0)

66 (27.4)

133 (27.7)

7.6 (2.5)

7.4 (2.6)

7.5 (2.6)

Baseline use of:
Methotrexate, n (%)
Mean (SD) dose (mg/week)
Oral corticosteroids, n (%)
Mean (SD) dose (mg/day)

n = 188, 189, 377
n = 227, 232, 459
n = 236, 237, 473
4
Among patients with dactylitis/enthesitis at baseline
BSA body surface area, CDAI Clinical Disease Activity Index, DAPsA Disease Activity in Psoriatic Arthritis, IV intravenous, HAQ-DI Health Assessment QuestionnaireDisability Index, PASDAS Psoriatic ArthritiS Disease Activity Score, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, SD standard deviation, SHS Sharp/
van der Heijde score, VAS visual analog scale
1
2
3
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and 0.82, respectively, and 0.54 for week 52 change
scores.
During the controlled period, mean changes from
week 0 to week 24 in total PsA-modified SHS were
− 0.36 in the IV golimumab group and 1.95 in the placebo group (p < 0.001). The greater inhibition of structural damage progression observed in the IV golimumab
group at week 24 was sustained through week 52 (mean
change in total PsA-modified SHS from week 0 to week
52, − 0.49). Patients randomized to placebo who crossed
over to IV golimumab at week 24 (placebo→golimumab)
exhibited a dampening of radiographic progression from
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week 24 to week 52 (mean change total PsA-modified
SHS, − 0.64) relative to the period of placebo treatment
(1.95), such that their overall mean change in SHS from
week 0 to week 52 was 0.76 (Fig. 1a).
Radiographic progression and disease activity assessed
via composite indices

Across composite indices, golimumab-treated patients
demonstrated less radiographic progression than
placebo-treated patients at week 24 within each category
of disease activity (Figs. 1b, d; 2a; 3a; 4a). The observed
treatment effect was sustained through week 52, i.e.,

Fig. 1 Mean changes from baseline in total PsA-modified SHS. Results are shown for all patients at week 24 and week 52 (a); patients who did
and did not achieve MDA at week 24 (b) and week 52 (c); and patients who did and did not achieve VLDA at week 24 (d) and week 52 (e). IV,
intravenous; MDA, minimal disease activity; PsA, psoriatic arthritis; SD, standard deviation; SE, standard error; SHS, Sharp/van der Heijde score;
VLDA, very low disease activity
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Fig. 2 Mean changes from baseline in total PsA-modified SHS by PASDAS-defined disease activity state. Results are shown at week 24 (a) and
week 52 (b). HDA, high disease activity; IV, intravenous; LDA, low disease activity; ModDA, moderate disease activity; PASDAS, Psoriatic ArthritiS
Disease Activity Score; PsA, psoriatic arthritis; SD, standard deviation, SHS, Sharp/van der Heijde score

numerically less radiographic progression was seen from
week 0 to week 52 with golimumab than placebo→golimumab treatment regardless of composite index
employed or disease activity state achieved (Figs. 1c, e;
2b; 3b; 4b).
When comparing the extent of radiographic progression
across disease activity categories among patients receiving
golimumab beginning at week 0, at both week 24 (Figs. 1b,
d; 2a; 3a; 4a) and week 52 (Figs. 1c, e; 2b; 3b; 4b), individuals
achieving lower levels of disease activity demonstrated numerically less disease progression than those whose disease
activity remained high. For example, mean SHS changes in
golimumab-randomized patients who achieved MDA or
VLDA were − 0.83 and − 0.91, respectively, compared with
− 0.05 and − 0.26 in patients who did not, at week 24 (Fig. 1b,
d) and − 1.16 and − 1.49, compared with 0.03 and − 0.30 in

patients who did not, at week 52 (Fig. 1c, e). Similarly, mean
SHS changes from week 0 to week 52 were − 1.01, − 0.20,
and 0.54 in golimumab-randomized patients demonstrating
PASDAS-defined remission+low disease activity (LDA),
moderate disease activity (ModDA), and high disease activity
(HDA), respectively (Fig. 2b) and − 0.88, − 0.48, and 0.41 in
patients demonstrating DAPsA-defined remission+LDA,
ModDA, and HDA, respectively (Fig. 3b). Consistently, mean
SHS changes from week 0 to week 52 were − 1.06 and − 0.81
in golimumab-randomized patients exhibiting CDAI-defined
remission and LDA, respectively, compared with 0.20 and
1.11 in patients with CDAI-defined ModDA and HDA, respectively (Fig. 4b).
Of interest, patients receiving golimumab from week 0
to week 52 who did not achieve MDA or VLDA by week
52 still demonstrated numerically less radiographic
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Fig. 3 Mean changes from baseline in total PsA-modified SHS by DAPsA-defined disease activity state. Results are shown at week 24 (a) and
week 52 (b). DAPsA, Disease Activity in Psoriatic Arthritis; HDA, high disease activity; IV, intravenous; LDA, low disease activity; ModDA, moderate
disease activity; PsA, psoriatic arthritis; SD, standard deviation; SHS, Sharp/van der Heijde score

progression than patients receiving placebo→golimumab, i.e., respective mean SHS changes from week 0 to
week 52 were 0.03 vs 1.50 in MDA nonresponders and
− 0.30 vs 1.45 in VLDA nonresponders (Fig. 1c, e). The
observation of diminished radiographic progression in
golimumab- vs. placebo→golimumab-treated patients
despite still exhibiting HDA at week 52 was also observed for PASDAS (0.54 vs 3.81; Fig. 2b), DAPsA (0.41
vs 1.27; Fig. 3b), and CDAI (1.11 vs 1.75; Fig. 4b) composite indices.

Discussion
The fully human anti-TNFα monoclonal antibody golimumab has demonstrated long-term clinical efficacy and
inhibition of structural damage in patients with
moderate-to-severe PsA [7–10]. Given the importance of

assessing the diverse manifestations in patients with PsA
[5], we conducted post hoc analyses to assess changes in
radiographic progression in patients with varying levels
of composite index-defined disease activity following
treatment with IV golimumab or placebo in the large
phase 3 GO-VIBRANT PsA trial [9, 10]. Composite endpoints were chosen for these analyses because they allow
the assessment of multiple clinical manifestations in a
single instrument [21]. Additionally, composite endpoints only require a single test of hypothesis and generally have no multiplicity issues, thereby potentially
simplifying testing schemes in clinical trials [30]. As no
consensus has been reached on the ideal composite endpoint [5], and each has advantages and limitations related to ease of use and domains included, we evaluated
several indices, including the MDA, VLDA, PASDAS,
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Fig. 4 Mean changes from baseline in total PsA-modified SHS by CDAI-defined disease activity state. Results are shown at week 24 (a) and week
52 (b). CDAI, Clinical Disease Activity Index; HDA, high disease activity; IV, intravenous; LDA, low disease activity; ModDA, moderate disease
activity; PsA, psoriatic arthritis; SD, standard deviation; SHS, – Sharp/van der Heijde score

DAPsA, and CDAI. Importantly, golimumab-treated patients exhibited less radiographic progression than
placebo-treated patients, regardless of the composite
index employed or extent of clinical disease activity
attained. Further, the greater inhibition of structural
damage progression observed with IV golimumab vs placebo at week 24 appeared to be sustained through week
52, despite placebo crossover to golimumab at week 24,
indicating prompt treatment can have longstanding implications on structural progression.
Of interest, even in patients who did not achieve
MDA/VLDA or who sustained high levels of disease activity assessed using the PASDAS, DAPsA, or CDAI indices, patients treated with golimumab IV exhibited less
radiographic progression than those receiving placebo.
This observation is consistent with other studies that
have shown a disconnect between clinical and radiographic outcomes, suggesting a direct effect of golimumab on radiographic progression that is at least partially
independent of its effect on clinical measures of disease
activity. For example, evidence of an uncoupling of

disease activity and radiographic progression was observed in adalimumab-treated PsA patients, whereby, irrespective of MTX use, inhibition of radiographic
progression was greater than expected based on control
of clinical disease activity alone [31]. Additionally, in RA
patients treated via TNF inhibition, benefits in radiographic progression were observed among patients not
achieving clinical improvement [32–34].
We hypothesize that these observations could relate to
a direct effect of TNF inhibition on reducing osteoclast
(OC) activity. Specifically, cultured peripheral blood
mononuclear cells (PBMCs) obtained from patients with
PsA have been shown to spontaneously release high
quantities of biologically active TNFα [2], and in patients
with PsA and other inflammatory arthritides, the PBMC
pool is enriched with OC precursors (OCPs) [2, 35, 36].
Notably, increased levels of OCPs in PsA patients have
been shown to be most pronounced in those with observable bone erosions, and blocking TNFα in such patients markedly decreased levels of circulating OCPs [2].
Further, in a small study of patients with RA or PsA,
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OCP populations correlated with peripheral blood TNFα
levels [37]. Thus, observations to date suggest TNFα is
pivotal in promoting OCP formation. The resulting OCs
express receptors for macrophage colony-stimulating factor and receptor activator of nuclear factor-κB ligand
(RANKL). RANKL, a member of the TNF family of cytokines, is the primary mediator of OC-induced bone resorption, as it is required for OC survival and activation
through interaction with its receptor RANK [35, 36].
Thus, the observed synergy between TNFα and RANK in
mediating OC-induced bone resorption [2, 38] suggests
that the reduced OCP susceptibility to chemokine (e.g.,
TNFα) signals afforded by golimumab treatment could
contribute to its direct control of structural disease progression. Indeed, in a previously reported study of PsA patients, SC golimumab had a beneficial impact on several
biomarkers of bone remodeling, including monocyte/
macrophage-derived chemokines [39].
The strengths of our analyses include a large patient
population (N = 474) and moderate-to-good agreement
in radiographic scores between independent central
radiographic readers. Given the more variable occurrence and typically slower progression of structural damage generally observed in PsA than in other erosive
diseases, as well the length of time required to fully assess radiographic outcomes, similar evaluations extending beyond 1 year would be useful to confirm our
findings. Further, incorporation of biomarker determinations and assessments of new bone formations into
future studies could enhance understanding the mechanism of a direct effect of golimumab on radiographic progression. While beyond the scope of the current post
hoc analyses, prospective studies are needed to identify
the composite endpoint(s) demonstrating strong correlation with inhibition of radiographic progression. As
well, findings derived from patients enrolled into this
randomized clinical trial may not be fully generalizable
to a more heterogeneous PsA population.

Conclusions
The extent of structural damage inhibition afforded by
up to 1 year of IV golimumab treatment paralleled levels
of PsA activity, with greater progression of structural
damage observed in patients with sustained higher disease activity. Golimumab-randomized patients not
achieving low levels of disease activity across a number
of composite indices still demonstrated far less progression of structural damage than placebo-randomized PsA
patients, suggesting a direct favorable effect of golimumab on radiographic progression at least partially independent of its effect on disease activity. Our findings
provide additional evidence of a potential uncoupling of
clinical and radiographic responses to TNF inhibition in
patients with PsA.
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